Chemotherapy
ASCO guideline helps clinicians address cannabis use ‘head on’ with their patients
Broader accessibility to and use of cannabis and cannabinoids has created formidable challenges for clinicians who treat people with cancer.
Multidrug regimen could be ‘curative’ option for aggressive lymphoma
A simultaneous, multidrug, multi-targeted treatment regimen produced remissions in patients with certain types of relapsed or refractory diffuse large B-cell lymphoma in a phase 1b/phase 2 study.
FDA approves Imfinzi regimen for advanced endometrial cancer
The FDA approved the use of durvalumab in combination with carboplatin and paclitaxel followed by single-agent durvalumab for women with mismatch repair-deficient primary advanced or recurrent endometrial cancer.
Decentralization of cancer care could reduce greenhouse gas emissions by one-third
CHICAGO — Telemedicine substantially reduced greenhouse gas emissions associated with travel to in-person clinical visits for cancer care, results from a retrospective study presented at ASCO Annual Meeting showed.
FDA approves Keytruda regimen for advanced endometrial cancer
The FDA approved the use of pembrolizumab in combination with chemotherapy for adults with primary advanced or recurrent endometrial carcinoma.
AI-driven algorithm yields ‘practical, scalable framework’ to increase palliative care use
CHICAGO — An algorithm-based default referrals system led to a fourfold increase in specialty palliative care use when implemented in a large community oncology network, results of a randomized study presented at ASCO Annual Meeting showed.
Primary ovarian insufficiency, reproductive cancers may be linked across generations
BOSTON — People with primary ovarian insufficiency have higher risk for breast cancer and borderline increased risk for ovarian cancer compared with the general population, and risks for some cancers extend to their relatives, data show.
Adagrasib delays progression of pretreated KRAS-mutant lung cancer
CHICAGO — Individuals with KRAS-mutant lung cancer treated with adagrasib experienced significantly prolonged PFS compared with docetaxel, randomized study results presented at ASCO Annual Meeting showed.
Positive results in lung cancer show benefits of subcutaneous bispecifics
CHICAGO — The addition of subcutaneous amivantamab to lazertinib demonstrated noninferior pharmacokinetics and objective response rate compared with intravenous amivantamab, results from a phase 3 study showed.
A 100% response rate suggests dostarlimab is ‘definitive’ therapy for rectal cancer
CHICAGO — A phase 2 study evaluating dostarlimab in adults with mismatch repair-deficient locally advanced rectal cancer has maintained a 100% clinical complete response rate at a median follow-up of almost 18 months.